BR9814053A - Diésteres lipofìlicos de agentes de quelação - Google Patents

Diésteres lipofìlicos de agentes de quelação

Info

Publication number
BR9814053A
BR9814053A BR9814053-1A BR9814053A BR9814053A BR 9814053 A BR9814053 A BR 9814053A BR 9814053 A BR9814053 A BR 9814053A BR 9814053 A BR9814053 A BR 9814053A
Authority
BR
Brazil
Prior art keywords
diesters
chelating agents
treatment
condition
divalent metal
Prior art date
Application number
BR9814053-1A
Other languages
English (en)
Other versions
BR9814053B1 (pt
Inventor
Alexander Kozak
Israel Shapiro
Original Assignee
Pharm Limited D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharm Limited D filed Critical Pharm Limited D
Publication of BR9814053A publication Critical patent/BR9814053A/pt
Publication of BR9814053B1 publication Critical patent/BR9814053B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/76—Metal complexes of amino carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Steroid Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"DIéSTERES LIPOFìLICOS DE AGENTES DE QUELAçãO" A invenção apresenta diésteres estáveis de agentes de quelação de íons metálicos divalentes, processo para sua preparação e composições farmacêuticas dos mesmos. Compostos mais preferidos de acordo com a presente invenção são diésteres lipofílicos estáveis compreendendo um conjugado covalente de um BAPTA e um álcool farmaceuticamente aceitável. Os diésteres são úteis num método para o tratamento de uma condição ou doença relacionada a um excesso de íons metálicos divalentes e, em particular para o tratamento de uma condição ou doença relacionada com elevados níveis de íons cálcio intracelular, tais como na isquemia cerebral ou cardíaca, ataque, epilepsia, doença de Alzheimer ou arritmia cardíaca e na cirurgia de coração exposto.
BRPI9814053-1A 1997-09-28 1998-09-27 diésteres lipofìlicos de agentes de quelação. BR9814053B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12184497A IL121844A0 (en) 1997-09-28 1997-09-28 Lipophilic diesters of chelating agents
IL121844 1997-09-28
PCT/IL1998/000468 WO1999016741A2 (en) 1997-09-28 1998-09-27 Lipophilic diesters of chelating agents

Publications (2)

Publication Number Publication Date
BR9814053A true BR9814053A (pt) 2000-09-26
BR9814053B1 BR9814053B1 (pt) 2010-11-30

Family

ID=11070677

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9814053-1A BR9814053B1 (pt) 1997-09-28 1998-09-27 diésteres lipofìlicos de agentes de quelação.

Country Status (17)

Country Link
US (1) US6458837B1 (pt)
EP (1) EP1027325B1 (pt)
JP (1) JP4668411B2 (pt)
KR (1) KR100545487B1 (pt)
AT (1) ATE235457T1 (pt)
AU (1) AU739835B2 (pt)
BR (1) BR9814053B1 (pt)
CA (1) CA2304700C (pt)
CZ (1) CZ300455B6 (pt)
DE (1) DE69812679T2 (pt)
DK (1) DK1027325T3 (pt)
ES (1) ES2195393T3 (pt)
HU (1) HU229161B1 (pt)
IL (2) IL121844A0 (pt)
NZ (1) NZ503085A (pt)
PT (1) PT1027325E (pt)
WO (1) WO1999016741A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350780B1 (en) * 1995-07-28 2002-02-26 Allergan Sales, Inc. Methods and compositions for drug delivery
WO2001041756A2 (en) * 1999-12-02 2001-06-14 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
AUPS255402A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with oxidative stress
IL151921A0 (en) * 2002-09-25 2003-04-10 Pharma Ltd D Liphopilic diesters of chelating agent for inhibition of enzyme activity
IL157396A0 (en) * 2003-08-14 2004-02-19 Dpharm Ltd Use of lipophilic diesters of chelating agent for the treatment of amyloidosis and atherosclerosis
WO2008099210A2 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
CN102093234B (zh) * 2009-11-26 2014-06-18 福州乾正药业有限公司 一种二元酯酸的氨丁三醇盐化合物及其制备方法和药物应用
US9415032B2 (en) 2011-10-05 2016-08-16 The Johns Hopkins University Membrane activated chelators and use in the prevention and treatment of parasitic infection
CN103373957A (zh) * 2012-04-12 2013-10-30 成都苑东药业有限公司 一种具有神经细胞保护作用的螯合物
WO2015092789A1 (en) * 2013-12-17 2015-06-25 D-Pharm Ltd. Onium salts of lipophilic diesters of chelating agents
CN107315915A (zh) * 2017-06-28 2017-11-03 上海联影医疗科技有限公司 一种医疗手术模拟方法及***

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3479535A (en) * 1966-11-23 1969-11-18 Us Army Symmetrical pulse generator controlled by self-resetting snap diodes
US3497535A (en) 1967-07-25 1970-02-24 Geigy Chem Corp Stabilization of fats and oils with esters of edta and related compounds
US3751440A (en) * 1971-08-30 1973-08-07 Ciba Geigy Corp Metal complexes of n,n-dialkylesters of ethylenedinitrilotetraacetic acid and and compositions stabilized thereby
JPS5867652A (ja) * 1981-10-16 1983-04-22 Dai Ichi Pure Chem Co Ltd エチレンジアミン四酢酸−ｎ，ｎ′−ジ（２−エチルヘキシル）エステル
JPS59168442A (ja) * 1983-03-16 1984-09-22 Fuji Photo Film Co Ltd 画像形成方法
US4603161A (en) * 1985-06-14 1986-07-29 Olin Corporation Selected oxyalkylated 2,6-dialkylphenol compounds and their use as stabilizers of organic materials against oxidative degradation
US4849362A (en) 1988-05-19 1989-07-18 Smithkline Beckman Corporation Fluorescent intracellular calcium indicators
US5453517A (en) * 1992-02-25 1995-09-26 Molecular Probes, Inc. Reactive derivatives of bapta used to make ion-selective chelators
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
US5618513A (en) * 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides

Also Published As

Publication number Publication date
ES2195393T3 (es) 2003-12-01
HUP0003517A2 (hu) 2001-02-28
IL135097A (en) 2009-09-01
WO1999016741A3 (en) 1999-07-01
DK1027325T3 (da) 2003-07-21
WO1999016741A2 (en) 1999-04-08
HUP0003517A3 (en) 2003-06-30
PT1027325E (pt) 2003-08-29
DE69812679D1 (de) 2003-04-30
DE69812679T2 (de) 2004-03-04
JP2001518458A (ja) 2001-10-16
CZ20001065A3 (cs) 2000-08-16
NZ503085A (en) 2002-09-27
BR9814053B1 (pt) 2010-11-30
EP1027325B1 (en) 2003-03-26
KR100545487B1 (ko) 2006-01-24
KR20010015634A (ko) 2001-02-26
CZ300455B6 (cs) 2009-05-20
AU9365198A (en) 1999-04-23
JP4668411B2 (ja) 2011-04-13
HU229161B1 (en) 2013-09-30
US6458837B1 (en) 2002-10-01
AU739835B2 (en) 2001-10-18
ATE235457T1 (de) 2003-04-15
EP1027325A2 (en) 2000-08-16
IL121844A0 (en) 1998-02-22
CA2304700A1 (en) 1999-04-08
CA2304700C (en) 2010-10-26

Similar Documents

Publication Publication Date Title
BR9814053A (pt) Diésteres lipofìlicos de agentes de quelação
MX9203667A (es) Sales de bis-dimetoximetil (trimetoxibencil)quinolino, su preparacion y composicines farmaceuticas que las contienen.
DE69520768D1 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
CA2293470A1 (en) Benzimidazole derivatives
BR0209185A (pt) Amidas de ácido antranìlico, processos para produção das mesmas, uso das mesmas como agentes anti-arrìtmicos, bem como preparações farmacêuticas das mesmas
BR9811774A (pt) Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp
EP1024802A4 (en) (3SI (R), 4SI (R)) - SG (D) -TETRAHYDROCANNABINOLIC ACID AS AN INFLAMMATORY INHIBITOR AND ANALGESICA
RU94042935A (ru) Водорастворенные комплексы включения соединений бензотиофена с водорастворимыми циклодекстринами, способ их получения и фармацевтический состав
ATE299710T1 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
MY130035A (en) Antiviral compounds
KR950031059A (ko) 골다공증 치료용 약제학적 조성물
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
BR9809117A (pt) Composição de gel retardado de liberação prolongada, processo de produzir a mesma, formulação farmacêutica,e , processos de tratamento de uma indicação , de uma doença, e de uma inflamação com uma composição de liberação prolongada
PT97743A (pt) Processo para a preparacao de composicoes farmaceuticas comportando baclofeno como ingrediente activo destinadas ao tratamento da angina de peito
RU95106821A (ru) Циклопептиды, способ их получения, фармацевтическая композиция и способ ее получения
BG100911A (en) Biophosphonic acids-sontaining wet-granulated form
CA2282378A1 (en) Pharmaceutical composition
IL137362A (en) Pharmaceutical compositions containing 2-amino-2[2-(4-octylphenyl) ethyl] propane -1 3,diol and salts thereof
MX9603300A (es) Derivados de la 4-sulfonilbenzoilguanidina o la 4-sulfinilbenzoilguanidina.
PT100415A (pt) Novas morfolinas de accao farmaceutica, e processo para a sua preparacao
BR9913425A (pt) Derivados de ácido hidroxìmico insaturado comoinibidores parp
BR9509517A (pt) Composição lipossômica composição farmacéutica e processo para a preparação de composições lipossómicas
BR9810072A (pt) Formulação farmacêutica semi-sólida contendo dexcetoprofen trometamol
IT8220757A0 (it) Sale di magnesio dell'acido chenodesossicolico e dell'acido ursodesossicolico, processo per lasua preparazione e composizioni terapeutiche che lo contengono come principio attivo.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/11/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)